Analysis Group Experts from HEOR, Epidemiology & Market Access Practice to Present Award-Winning Research Posters at AMCP Nexus Meeting

October 15, 2026

Analysis Group’s HEOR, Epidemiology & Market Access practice will present 13 posters, including a silver ribbon awardee, at the Academy of Managed Care Pharmacy’s (AMCP’s) annual Nexus meeting, which will be held Oct. 26-29, 2026 in San Diego, California.

Silver Ribbon

  • “Real-world healthcare resource utilization and costs among patients with small cell lung cancer receiving second-line and third-line therapy in the US,” coauthored by an Analysis Group team – including Managing Principal Keith A. Betts, Vice President Yan Wang, and Associates Shuang Wang, Tszshan Ma, and Linshanshan Wang – in collaboration with researchers from Jazz Pharmaceuticals (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 278.

Additional poster presentations include

  • “Cost per complete responder for epcoritamab + lenalidomide and rituximab (R2) versus tafasitamab + R2 in relapsed or refractory follicular lymphoma: A US Medicare perspective,” coauthored by an Analysis Group team – including Managing Principal Elyse Swallow, Vice President Wei Gao, Manager Taiji Wang, and Associate Taylor Wang – in collaboration with researchers from Atrium Health Levine Cancer Institute, Genmab, and AbbVie (sponsors). Wednesday, October 28, 12:00–1:00p.m. Poster 104.
  • “Transforming the Burden of Hyperphagia in Bardet-Biedl Syndrome: 6-Month Real-World Outcomes from the RESTORE Study Transforming the Burden of Hyperphagia in Bardet-Biedl Syndrome: 6-Month Real-World Outcomes from the RESTORE Study,” coauthored by an Analysis Group team – including Managing Principal Min Yang, Manager Su Zhang, and Associate Jingyi Liu – in collaboration with researchers from the Marshfield Clinic Research Institute, the University of Alberta, Children’s Mercy, and Rhythm Pharmaceuticals (sponsor). Wednesday, October 28, 12:00–1:00p.m. Poster 119.
  • “Characterization and treatment patterns of high-cost patients with uncomplicated urinary tract infections in the United States,” coauthored by an Analysis Group team – including Principal François Laliberté, Manager Chi Gao, Associate Jordan A. Burdeau, Analyst Bo Liu, Senior Research Professional Kaixin Zhang – in collaboration with researchers from GSK (sponsor). Wednesday, October 28, 12:00–1:00p.m. Poster 193.
  • “Impact of extended antibiotic treatment duration on post treatment healthcare utilization in patients with uncomplicated urinary tract infections in the United States,” coauthored by an Analysis Group team – including Principal François Laliberté, Manager Chi Gao, Associate Jordan A. Burdeau, Analyst Bo Liu, and Senior Research Professional Sophie Ma – in collaboration with researchers from the University of Georgia College of Pharmacy and GSK (sponsor). Wednesday, October 28, 12:00–1:00p.m. Poster 194.
  • “Exploration of real-world healthcare resource utilization (HCRU) following ibrexafungerp initiation in patients with vulvovaginal candidiasis (VVC),” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Rose Chang, Associates Naiyu Chen and Taylor L. Wang – in collaboration with researchers from the University of California-Davis Medical Center, and GSK (sponsor). Wednesday, October 28, 12:00–1:00p.m. Poster 196.
  • “Economic Burden of Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma in the US,” coauthored by an Analysis Group team – including Vice President Yan Wang and Manager Cheryl Xiang – in collaboration with researchers from Johnson & Johnson Innovative Medicine (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 251. 
  • “Cost per Complete Response and Total Cost of Care of Nadofaragene Firadenovec Versus Other FDA-Approved Bladder Preserving Therapies in BCG-Unresponsive High-Risk NMIBC: A US Payer Perspective Analysis,” coauthored by an Analysis Group team – including Managing Principal Min Yang, Vice President Xinglei Chai, and Associate Michael K. Xu – in collaboration with researchers from the University of Iowa, the University of Texas Southwestern Medical Center, and Ferring (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 255.
  • “Treatment patterns and event-free survival among Bacillus Calmette-Guérin-unresponsive patients with high-risk non–muscle-invasive bladder cancer with carcinoma in situ,” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Manager Carmine Rossi, Associate Elizabeth Hore, and Senior Analyst Steven Liu – in collaboration with researchers from the University of Wisconsin and Johnson & Johnson (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 268.
  • “Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis,” coauthored by an Analysis Group team – including Managing Principal Yan Song, Vice President Yan Wang, and Associate Ariel Chao – in collaboration with researchers from Massachusetts General Hospital, Harvard Medical School, and Novo Nordisk (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 300.
  • “Real-world disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis,” coauthored by an Analysis Group team – including Managing Principal Yan Song, Vice President Yan Wang, and Associate Ariel Chao – in collaboration with researchers from Massachusetts General Hospital, Harvard Medical School, and Novo Nordisk (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 303.
  • “Economic burden of refractory chronic cough and unexplained chronic cough among older patients (≥65 years of age): results from two databases of Medicare beneficiaries,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Rose Chang, Manager Catherine Nguyen, Associate Adina Zhang, and Senior Analysts Tingxi Long and Leili Young-Xu – in collaboration with researchers from the University of California-Davis and GSK (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 359.
  • “Treatment patterns and exacerbations among patients with chronic obstructive pulmonary disease by payer type: Findings from the DUALITY patient journey study,” coauthored by an Analysis Group team – including Manager Ambika Satija and Associate Jessica Smith – in collaboration with researchers from the University of Miami and AstraZeneca (sponsor). Wednesday, October 28, 1:00–2:00p.m. Poster 362.